AUPH

Voclosporin Ophthalmic Solution

Dry Eye Syndrome

Phase 2/3 (Top-line Data)

Exp Date

Q4 2020

Amp Volatility Score

Catalyst Info & Data Links

TITLE: Voclosporin for dry eye syndrome - Top-Line, Primary and Secondary Data

  • ClinicalTrial.gov (NCT04147650): Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome (AUDREY)


WHAT IS THE CATALYST EVENT?


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q4 2020


PAST DATA/EVENTS 


PRESS RELEASES

POSTERS


PRESENTATIONS

PUBLICATIONS


COMPETITORS


Calcineurin inhibitor:

MARKET

MECHANISM OF ACTION / RATIONALE

Updated by HC

AUPH, Voclosporin, AUDREY, Top-line Data

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

AUPH Ph3 data in lupus nephrit...

AUPH reported encouraging phase 3 results in December (12/4/19) in lupus nephritis, an inflammation of the kidney caused by SLE. Its calcineurin inhibitor drug candidate voclosporin met its primary en...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon